Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sensitizing energistic agent of chemotherapy medicine for treating tumour

A technology of chemotherapeutic drugs and synergists, which is applied in the direction of antineoplastic drugs, drug combinations, and pharmaceutical formulations, and can solve the problems of unsustainable drug effects, easy decomposition, and affecting efficacy.

Inactive Publication Date: 2005-08-10
EAST CHINA UNIV OF SCI & TECH +1
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But unfortunately: the research found that water-soluble EGCG has two major disadvantages: one is poor stability, easy to decompose, short-term existence in the body, and the drug effect is difficult to last; the other is poor membrane permeability, which is not easy to be absorbed by cells into cells , or its bioavailability is low, and it is difficult to accumulate at the target point to achieve an effective concentration, thus affecting its efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sensitizing energistic agent of chemotherapy medicine for treating tumour
  • Sensitizing energistic agent of chemotherapy medicine for treating tumour

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] Example 1 Tumor inhibitory effect when fat-soluble EGCG is used in combination with doxorubicin

[0058] Firstly, the nude mouse KB-A-1 cell solid tumor model was established according to the conventional method, and then the tumor inhibition test in Example 1 was carried out in random groups.

[0059] Specific conditions for the antitumor test using fat-soluble EGCG in combination with the antitumor drug doxorubicin:

[0060] Group 1 is a blank group that only gives normal saline and does not administer drugs;

[0061] The second group is the administration of 5 μg / ml doxorubicin drug group;

[0062] The third group was the group that administered 40 mg / kg fat-soluble EGCG;

[0063] Group 4 was administered with 20 mg / kg fat-soluble EGCG+5 μg / ml doxorubicin;

[0064] Group 5 was administered with 40 mg / kg fat-soluble EGCG+5 μg / ml doxorubicin.

[0065] The experimental results are shown in the table below:

[0066] group

[0067] From the comparison of th...

Embodiment 2

[0068] Example 2 The antitumor effect of fat-soluble EGCG combined with antitumor drug vincristine.

[0069] Firstly, nude mouse KB-A-1 cell solid tumor models were established according to conventional methods, and then the tumor inhibition experiments were performed in random groups.

[0070] Specific conditions for the anti-tumor test using fat-soluble EGCG and vincristine in combination:

[0071] The first group was given normal saline, and the blank group without drugs;

[0072] The 2nd group is to apply the vincristine drug group of 4 μ g / ml;

[0073] The third group was the group that administered 40 mg / kg fat-soluble EGCG;

[0074] The fourth group was the drug group of 20mg / kg fat-soluble EGCG+4μg / ml vincristine;

[0075] Group 5 was given 40mg / kg fat-soluble EGCG+4μg / ml vincristine drug group.

[0076] The experimental results are listed in the table below.

[0077] group

1

2

3

4

5

Average tumor weight (g)

1.61...

Embodiment 3

[0080] Example 3 Antitumor effect of fat-soluble EGCG combined with antitumor drug mitomycin.

[0081] Firstly, nude mouse KB-A-1 cell solid tumor models were established according to conventional methods, and then the tumor inhibition experiments were performed in random groups.

[0082] The specific conditions for the anti-tumor test using fat-soluble EGCG in combination with the anti-tumor drug mitomycin:

[0083] Group 1 is a blank group that only gives normal saline and does not administer drugs;

[0084] Group 2 was the drug group administered with 4 μg / ml mitomycin;

[0085] The third group was the group that administered 40 mg / kg fat-soluble EGCG;

[0086] The 4th group is the administration group of 20mg / kg fat-soluble EGCG+4μg / ml mitomycin;

[0087] Group 5 was administered with 40mg / kg fat-soluble EGCG+4μg / ml mitomycin.

[0088] The experimental results are listed as follows:

[0089] group

1

2

3

4

5

Average tumor w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A sensitizing synergist of chemicotherapeutic medicine for treating tumor is a liposoluble epigallocatechol gallate (C22H35O11-Ro).

Description

technical field [0001] The invention relates to a sensitization synergist of chemotherapy drugs for treating tumors, in particular to a sensitization synergist which can be used in combination with existing anti-tumor chemotherapy drugs to form a class of anti-tumor drugs with high tumor inhibition rate , an invention for the use of a compound. Background technique [0002] Drug resistance is a well-known failure phenomenon in the process of disease treatment. However, in the process of treating tumors, due to the particularity of the treatment target, multidrug resistance is also prone to occur, resulting in reduced chemotherapy effects and treatment failure. [0003] Multidrug resistance (MDR for short) refers to the generation of resistance to a variety of natural anti-tumor drugs with different structures and mechanisms of action when cancer cells are exposed to a natural anti-tumor drug. drug resistance. Cancer patients often develop multidru...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/704A61K45/06A61P35/00
Inventor 顾国兴刘建文魏东芝卢艳花王磊
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com